10 completed, 1 recruiting. 7 Phase 1, 3 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Recruiting 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Patents as Topic: new trials by email Literature Review of Patents as Topic trials Research Report on Patents as Topic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. OMTX705, Pembrolizumab, Tislelizumab (BGB-A317) - Advanced Solid Tumor | Phase 1 | Recruiting | Oncomatryx Biopharma S.L. | 150 | 2022-10-20 | 2025-11-25 |
| Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product Eszopiclone 3mg Test Drug T-1 Coated Tablets, Eszopiclone 3mg Test Drug T-2 Coated Tablets, Eszopiclone 3mg Reference Product Coated Tablets - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 28 | 2022-04-11 | 2022-04-27 |
| Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product, Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 10 | 2020-11-21 | 2021-02-10 |
| Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug, Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 30 | 2020-10-24 | 2021-02-10 |
| Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product Desogestrel 0.075 MG - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 30 | 2020-01-11 | 2020-06-09 |
| Bioavailability of Dienogest 2.0 mg With Regards to Reference Product Dienogest 2.0 mg Test Drug, Dienogest 2.0 mg Reference Product - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 30 | 2019-12-07 | 2020-01-18 |
| Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug, Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 10 | 2019-11-09 | 2019-12-10 |
| Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Metoclopramide, Placebo - Prolonged First Stage of Labor | Phase 4 | Completed | Ain Shams University | 250 | 2013-07-01 | 2017-03-10 |
| Immune Globulin Subcutaenous (Human), 20% Immune Globulin Subcutaneous (Human), 20%, Immune Globulin Intravenous (Human), 10%, Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 55 | 2011-06-20 | 2021-05-05 |
| Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel - Non-Small Cell Lung Cancer | Phase 2 | Completed | OSI Pharmaceuticals | 103 | 2004-02-01 | 2012-08-09 |
| Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Tarceva (Trademark) (erlotinib HCl, OSI-774) - Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy | Phase 2 | Completed | OSI Pharmaceuticals | 43 | 2003-11-05 | 2018-02-08 |
Carcinoma, Non-Small-Cell Lung (2) · Primary Immunodeficiency Diseases (1)
Laboratorios Andromaco S.A. (6) · OSI Pharmaceuticals (2) · Ain Shams University (1) · Baxalta now part of Shire (1) · Oncomatryx Biopharma S.L. (1)
Chile (5) · United States (3) · Austria (1) · Germany (1) · Hungary (1) · India (1) · Saudi Arabia (1) · Spain (1) · Sweden (1) · United Kingdom (1)
PMID 18281658, PMID 27613250, PMID 30626238, PMID 31268374, PMID 31609464, PMID 34036490